CA2467455C - Method of detection of prostate cancer - Google Patents
Method of detection of prostate cancer Download PDFInfo
- Publication number
- CA2467455C CA2467455C CA 2467455 CA2467455A CA2467455C CA 2467455 C CA2467455 C CA 2467455C CA 2467455 CA2467455 CA 2467455 CA 2467455 A CA2467455 A CA 2467455A CA 2467455 C CA2467455 C CA 2467455C
- Authority
- CA
- Canada
- Prior art keywords
- methylation
- prostate
- subject
- sample
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 78
- 206010060862 Prostate cancer Diseases 0.000 title claims description 33
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims description 31
- 238000001514 detection method Methods 0.000 title abstract description 28
- 230000011987 methylation Effects 0.000 claims abstract description 167
- 238000007069 methylation reaction Methods 0.000 claims abstract description 167
- 102100030943 Glutathione S-transferase P Human genes 0.000 claims abstract description 133
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 claims abstract description 133
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims abstract description 67
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims abstract description 57
- 239000000523 sample Substances 0.000 claims description 76
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 239000013615 primer Substances 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 210000002700 urine Anatomy 0.000 claims description 41
- 238000004458 analytical method Methods 0.000 claims description 38
- 210000001519 tissue Anatomy 0.000 claims description 38
- 230000003321 amplification Effects 0.000 claims description 37
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 28
- 238000003752 polymerase chain reaction Methods 0.000 claims description 27
- 239000002751 oligonucleotide probe Substances 0.000 claims description 25
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 24
- 238000003745 diagnosis Methods 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 210000002307 prostate Anatomy 0.000 claims description 20
- 238000003753 real-time PCR Methods 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 16
- 108010070675 Glutathione transferase Proteins 0.000 claims description 15
- 206010029096 Neoplasm prostate Diseases 0.000 claims description 15
- 210000001124 body fluid Anatomy 0.000 claims description 15
- 102000005720 Glutathione transferase Human genes 0.000 claims description 14
- 101001023043 Homo sapiens Myoblast determination protein 1 Proteins 0.000 claims description 13
- 102100035077 Myoblast determination protein 1 Human genes 0.000 claims description 13
- 239000012472 biological sample Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003155 DNA primer Substances 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 5
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 5
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 239000013060 biological fluid Substances 0.000 claims 1
- 239000000090 biomarker Substances 0.000 abstract description 22
- 108020004414 DNA Proteins 0.000 description 44
- 238000001574 biopsy Methods 0.000 description 40
- 230000035945 sensitivity Effects 0.000 description 29
- 210000002381 plasma Anatomy 0.000 description 28
- 230000006607 hypermethylation Effects 0.000 description 24
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 20
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 20
- 230000009826 neoplastic cell growth Effects 0.000 description 18
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 17
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 238000013188 needle biopsy Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 238000002271 resection Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 4
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 201000001531 bladder carcinoma Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 231100000118 genetic alteration Toxicity 0.000 description 3
- 101150008380 gstp1 gene Proteins 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000007855 methylation-specific PCR Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 3
- 238000011471 prostatectomy Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 3
- 101150084750 1 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091029523 CpG island Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011472 radical prostatectomy Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010323 transrectal needle biopsy Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 101150076401 16 gene Proteins 0.000 description 1
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 101150087690 ACTB gene Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 101710112368 Glutathione S-transferase P 1 Proteins 0.000 description 1
- 101150013833 MYOD1 gene Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 238000001347 McNemar's test Methods 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000364021 Tulsa Species 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000018732 detection of tumor cell Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 101150042523 myod gene Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011473 radical retropubic prostatectomy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/125—Bisulfite(s)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33329601P | 2001-11-16 | 2001-11-16 | |
| US60/333,296 | 2001-11-16 | ||
| PCT/US2002/036784 WO2003044232A1 (en) | 2001-11-16 | 2002-11-15 | Method of detection of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2467455A1 CA2467455A1 (en) | 2003-05-30 |
| CA2467455C true CA2467455C (en) | 2013-03-19 |
Family
ID=23302188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2467455 Expired - Lifetime CA2467455C (en) | 2001-11-16 | 2002-11-15 | Method of detection of prostate cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7252935B2 (enExample) |
| EP (1) | EP1456413B1 (enExample) |
| JP (1) | JP4381142B2 (enExample) |
| AT (1) | ATE393240T1 (enExample) |
| AU (1) | AU2002352745A1 (enExample) |
| CA (1) | CA2467455C (enExample) |
| DE (1) | DE60226271T2 (enExample) |
| ES (1) | ES2304462T3 (enExample) |
| WO (1) | WO2003044232A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090226915A1 (en) | 2001-01-24 | 2009-09-10 | Health Discovery Corporation | Methods for Screening, Predicting and Monitoring Prostate Cancer |
| US20090215058A1 (en) * | 2001-01-24 | 2009-08-27 | Health Discovery Corporation | Methods for screening, predicting and monitoring prostate cancer |
| US20090215024A1 (en) * | 2001-01-24 | 2009-08-27 | Health Discovery Corporation | Biomarkers upregulated in prostate cancer |
| US8008012B2 (en) * | 2002-01-24 | 2011-08-30 | Health Discovery Corporation | Biomarkers downregulated in prostate cancer |
| US7718364B2 (en) * | 2003-03-25 | 2010-05-18 | John Wayne Cancer Institute | DNA markers for management of cancer |
| GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| WO2005024068A2 (en) | 2003-09-05 | 2005-03-17 | Sequenom, Inc. | Allele-specific sequence variation analysis |
| EP1689885B1 (en) * | 2003-10-20 | 2012-10-17 | St Vincent's Hospital Sydney Limited | Assessment of predisposition to cancer by quantitative determination of methylation in normal cells of healthy persons. |
| ES2801379T3 (es) | 2003-12-01 | 2021-01-11 | Epigenomics Ag | Métodos y ácidos nucleicos para el análisis de la expresión génica asociada con el desarrollo de trastornos proliferativos de células de próstata |
| JP4537050B2 (ja) * | 2003-12-25 | 2010-09-01 | 国立大学法人三重大学 | 前立腺癌、そのリスク又はその初期罹患の判定方法 |
| WO2005089414A2 (en) * | 2004-03-17 | 2005-09-29 | The Johns Hopkins University | Neoplasia diagnostic compositions and methods of use |
| AU2005230936B2 (en) | 2004-03-26 | 2010-08-05 | Agena Bioscience, Inc. | Base specific cleavage of methylation-specific amplification products in combination with mass analysis |
| US7608394B2 (en) * | 2004-03-26 | 2009-10-27 | Sequenom, Inc. | Methods and compositions for phenotype identification based on nucleic acid methylation |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| WO2005111232A2 (en) * | 2004-05-17 | 2005-11-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Silencing of tumor-suppressive genes by cpg-methylation in prostate cancer |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| US11105808B2 (en) | 2004-11-12 | 2021-08-31 | Health Discovery Corporation | Methods for screening, predicting and monitoring prostate cancer |
| US8268549B2 (en) * | 2005-04-15 | 2012-09-18 | University Of Maryland, Baltimore | Method and assay for determining methylation of GAL3 promoter for early diagnosis of prostate cancer |
| US7632634B2 (en) * | 2005-04-15 | 2009-12-15 | University Of Maryland Biotechnology Institute | Method and assay for early diagnosis of prostate cancer |
| US7851154B2 (en) * | 2005-07-22 | 2010-12-14 | Simon Daniel Spivack | GC tag-modified bisulfite genomic DNA sequencing for continuous methylation spectra |
| US20070059753A1 (en) * | 2005-09-15 | 2007-03-15 | Tatiana Vener | Detecting gene methylation |
| AU2006339538A1 (en) * | 2005-11-08 | 2007-09-13 | Euclid Diagnostics Llc | Materials and methods for assaying for methylation of CpG islands associated with genes in the evaluation of cancer |
| WO2007081791A2 (en) * | 2006-01-04 | 2007-07-19 | The Johns Hopkins University | Compare-ms:method rapid, sensitive and accurate detection of dna methylation |
| EP1984738A2 (en) | 2006-01-11 | 2008-10-29 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| WO2007133710A2 (en) | 2006-05-11 | 2007-11-22 | Raindance Technologies, Inc. | Microfluidic devices and methods of use thereof |
| EP2077912B1 (en) | 2006-08-07 | 2019-03-27 | The President and Fellows of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
| IL186935A0 (en) * | 2006-10-31 | 2008-02-09 | Veridex Llc | Prostate cancer field effect analysis methods and kits |
| US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| US20080213781A1 (en) * | 2007-02-15 | 2008-09-04 | Baden Jonathan F | Methods of detecting methylation patterns within a CpG island |
| JP2008202978A (ja) * | 2007-02-16 | 2008-09-04 | Hirosaki Univ | 前立腺癌の診断方法 |
| US20080254455A1 (en) * | 2007-04-12 | 2008-10-16 | Haiying Wang | Detecting prostate cancer |
| WO2008130623A1 (en) | 2007-04-19 | 2008-10-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| CN102016067A (zh) * | 2008-01-22 | 2011-04-13 | 维里德克斯有限责任公司 | 前列腺癌中gstp1高甲基化的检测 |
| WO2010009365A1 (en) | 2008-07-18 | 2010-01-21 | Raindance Technologies, Inc. | Droplet libraries |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
| US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
| US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
| US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
| US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
| US9279157B2 (en) * | 2009-02-06 | 2016-03-08 | The Regents Of The University Of California | EMX2 in cancer diagnosis and prognosis |
| US8528589B2 (en) | 2009-03-23 | 2013-09-10 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
| EP2486409A1 (en) | 2009-10-09 | 2012-08-15 | Universite De Strasbourg | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
| WO2011079176A2 (en) | 2009-12-23 | 2011-06-30 | Raindance Technologies, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| EP4484577A3 (en) | 2010-02-12 | 2025-03-26 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| WO2012045012A2 (en) | 2010-09-30 | 2012-04-05 | Raindance Technologies, Inc. | Sandwich assays in droplets |
| JP2014519310A (ja) | 2011-02-02 | 2014-08-14 | エクザクト サイエンシーズ コーポレイション | Ｄｎａメチル化のデジタル配列分析 |
| WO2012109600A2 (en) | 2011-02-11 | 2012-08-16 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
| US9150852B2 (en) | 2011-02-18 | 2015-10-06 | Raindance Technologies, Inc. | Compositions and methods for molecular labeling |
| EP3709018A1 (en) | 2011-06-02 | 2020-09-16 | Bio-Rad Laboratories, Inc. | Microfluidic apparatus for identifying components of a chemical reaction |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| EP3495817B1 (en) | 2012-02-10 | 2024-10-16 | Bio-Rad Laboratories, Inc. | Molecular diagnostic screening assay |
| WO2013165748A1 (en) | 2012-04-30 | 2013-11-07 | Raindance Technologies, Inc | Digital analyte analysis |
| US20140274767A1 (en) | 2013-01-23 | 2014-09-18 | The Johns Hopkins University | Dna methylation markers for metastatic prostate cancer |
| US20140274757A1 (en) | 2013-03-14 | 2014-09-18 | Marie K. Kirby | Differential Methylation Level of CpG Loci That Are Determinative of a Biochemical Reoccurrence of Prostate Cancer |
| WO2014172288A2 (en) | 2013-04-19 | 2014-10-23 | Raindance Technologies, Inc. | Digital analyte analysis |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| WO2015103367A1 (en) | 2013-12-31 | 2015-07-09 | Raindance Technologies, Inc. | System and method for detection of rna species |
| US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
| US10998178B2 (en) | 2017-08-28 | 2021-05-04 | Purdue Research Foundation | Systems and methods for sample analysis using swabs |
| US11427874B1 (en) | 2019-08-26 | 2022-08-30 | Epi One Inc. | Methods and systems for detection of prostate cancer by DNA methylation analysis |
| CN110951871B (zh) * | 2019-11-21 | 2024-01-05 | 瑞博奥(广州)生物科技股份有限公司 | Pca3和psa rna检测试剂盒和扩增体系 |
| CN116179694B (zh) * | 2022-11-02 | 2024-11-05 | 武汉艾米森生命科技有限公司 | 检测甲基化水平的试剂在制备前列腺癌诊断产品中的应用以及前列腺癌诊断试剂盒 |
| CN119391860B (zh) * | 2024-12-25 | 2025-03-21 | 慧算基因科技(上海)有限公司 | 一种用于胰腺癌术后mrd检测及动态监测的引物探针组合物、试剂盒及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017704A (en) * | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| AUPP312998A0 (en) * | 1998-04-23 | 1998-05-14 | Commonwealth Scientific And Industrial Research Organisation | Diagnostic assay |
| US6331393B1 (en) * | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| JP2004505612A (ja) * | 2000-03-31 | 2004-02-26 | ユニバーシティ・オブ・サザン・カリフォルニア | 食道腺ガンに関する後成的配列 |
| US20050021240A1 (en) * | 2000-11-02 | 2005-01-27 | Epigenomics Ag | Systems, methods and computer program products for guiding selection of a therapeutic treatment regimen based on the methylation status of the DNA |
| DE10112515B4 (de) * | 2001-03-09 | 2004-02-12 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungsmustern mit hoher Sensitivität |
-
2002
- 2002-11-15 JP JP2003545852A patent/JP4381142B2/ja not_active Expired - Lifetime
- 2002-11-15 CA CA 2467455 patent/CA2467455C/en not_active Expired - Lifetime
- 2002-11-15 US US10/295,483 patent/US7252935B2/en not_active Expired - Lifetime
- 2002-11-15 ES ES02789696T patent/ES2304462T3/es not_active Expired - Lifetime
- 2002-11-15 WO PCT/US2002/036784 patent/WO2003044232A1/en not_active Ceased
- 2002-11-15 AU AU2002352745A patent/AU2002352745A1/en not_active Abandoned
- 2002-11-15 EP EP20020789696 patent/EP1456413B1/en not_active Expired - Lifetime
- 2002-11-15 DE DE2002626271 patent/DE60226271T2/de not_active Expired - Lifetime
- 2002-11-15 AT AT02789696T patent/ATE393240T1/de not_active IP Right Cessation
-
2007
- 2007-07-06 US US11/825,479 patent/US7524633B2/en not_active Expired - Lifetime
-
2009
- 2009-03-16 US US12/404,964 patent/US20090181400A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7524633B2 (en) | 2009-04-28 |
| DE60226271T2 (de) | 2009-07-16 |
| EP1456413A4 (en) | 2005-05-18 |
| US20090181400A1 (en) | 2009-07-16 |
| AU2002352745A1 (en) | 2003-06-10 |
| ES2304462T3 (es) | 2008-10-16 |
| JP4381142B2 (ja) | 2009-12-09 |
| ATE393240T1 (de) | 2008-05-15 |
| DE60226271D1 (de) | 2008-06-05 |
| EP1456413A1 (en) | 2004-09-15 |
| US20080026395A1 (en) | 2008-01-31 |
| CA2467455A1 (en) | 2003-05-30 |
| US7252935B2 (en) | 2007-08-07 |
| EP1456413B1 (en) | 2008-04-23 |
| US20030124600A1 (en) | 2003-07-03 |
| JP2005509445A (ja) | 2005-04-14 |
| WO2003044232A1 (en) | 2003-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2467455C (en) | Method of detection of prostate cancer | |
| Jernimo et al. | Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer | |
| Jerónimo et al. | Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma | |
| DK2198042T3 (en) | New markers for bladder cancer detection | |
| US20100068720A1 (en) | Method and kit for detection of early cancer or pre-cancer using blood and body fluids | |
| AU2003218691A1 (en) | Method and device for determination of tissue specificity of free floating dna in bodily fluids | |
| ES2801379T3 (es) | Métodos y ácidos nucleicos para el análisis de la expresión génica asociada con el desarrollo de trastornos proliferativos de células de próstata | |
| EP1980856A1 (en) | Detecting prostate cancer | |
| Sepulveda et al. | CpG methylation analysis—current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology | |
| JP2022552400A (ja) | 特定の遺伝子のｃｐｇメチル化変化を利用した肝癌診断用組成物およびその使用 | |
| EP2304057A2 (en) | Method for the detection of ovarian cancer | |
| US20040146868A1 (en) | Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the development of peripheral zone prostate cancer | |
| US20170067119A1 (en) | Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders | |
| Melnikov et al. | Array-based multiplex analysis of DNA methylation in breast cancer tissues | |
| US20140141998A1 (en) | Neoplasia screening compositions and methods of use | |
| US20070117093A1 (en) | Heavymethyl assay for the methylation analysis of the gstpi gene | |
| US8617809B2 (en) | Neoplasia screening compositions and methods of use | |
| JP2010088406A (ja) | 癌患者の外科的手術後の治療選択方法及び予後診断 | |
| Eilers et al. | Prospective diagnostic efficiency of biopsy washing DNA GSTP1 island hypermethylation for detection of adenocarcinoma of the prostate | |
| Henrique et al. | Methylation-based biomarkers for early detection of urological cancer | |
| NIMO et al. | QUANTITATIVE GSTP1 HYPERMETHYLATION IN BODILY FLUIDS OF PATIENTS WITH PROSTATE CANCER | |
| Lopes | Quantitation of GSTP1 Methylation in Non-neoplastic Prostatic Tissue and Organ-Confined Prostate Adenocarcinoma | |
| Costaa et al. | Epigenetic markers for molecular detection of | |
| WO2009134468A2 (en) | Detecting prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20221115 |
|
| MKEX | Expiry |
Effective date: 20221115 |